Selected Reads

Smartkarma

Equity Bottom-Up

KPTI Long Equity Thesis Karyopharm (KPTI) is a commercial stage oncology company trading at the extremely distressed valuation of 1.4x EV/2024E revenue. Despite generating $115M+ in sales early into its launch...<a target="_blank" href="https://www.valueinvestorsclub.com/idea/KARYOPHARM_THERAPEUTICS_INC/9154188258">Read the article on Value Investor Club »</a>

United States

Karyopharm Therapeutics, Inc. provides biopharmaceutical products and services. The Company develops and discovers drugs for the treatment of cancer, inflammation, and diseases related to cell proliferation through activity modulation of critical pathways. Karyopham Therapeutics serves the healthcare industry throughout the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00